Biblio

Export 309 results:
Author Title [ Type(Desc)] Year
Filters: First Letter Of Keyword is T  [Clear All Filters]
Journal Article
M. E. Flanagan, Larson, E. B., Walker, R. L., C Keene, D., Postupna, N., Cholerton, B., Sonnen, J. A., Dublin, S., Crane, P. K., and Montine, T. J., “Associations between Use of Specific Analgesics and Concentrations of Amyloid-β 42 or Phospho-Tau in Regions of Human Cerebral Cortex.”, J Alzheimers Dis, vol. 61, no. 2, pp. 653-662, 2018.
C. Gonzalez, Mimmack, K. J., Amariglio, R. E., J Becker, A., Chhatwal, J. P., Fitzpatrick, C. D., Gatchel, J. R., Johnson, K. A., Katz, Z. S., Kuppe, M. K., Locascio, J. J., Udeogu, O. J., Papp, K. V., Premnath, P., Properzi, M. J., Rentz, D. M., Schultz, A. P., Sperling, R. A., Vannini, P., Wang, S., and Marshall, G. A., “Associations of the Harvard Automated Phone Task and Alzheimer's Disease Pathology in Cognitively Normal Older Adults: Preliminary Findings.”, J Alzheimers Dis, vol. 94, no. 1, pp. 217-226, 2023.
M. Ibarria, Alegret, M., Valero, S., Morera, A., Guitart, M., Cañabate, P., Moreno, M., Lara, S., Diego, S., Hernández, J., Tantinyá, N., Vera, M., Hernandez, I., Becker, J. T., Ruiz, A., Boada, M., and Tárraga, L., “Beneficial Effects of an Integrated Psychostimulation Program in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 2, pp. 559-66, 2016.
J. Peter, Schumacher, L. V., Landerer, V., Abdulkadir, A., Kaller, C. P., Lahr, J., and Klöppel, S., “Biological Factors Contributing to the Response to Cognitive Training in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 61, no. 1, pp. 333-345, 2018.
D. R. Galasko, Grill, J. D., Lingler, J. H., and Heidebrink, J. L., “A Blood Test for Alzheimer's Disease: It's about Time or Not Ready for Prime Time?”, J Alzheimers Dis, vol. 90, no. 3, pp. 963-966, 2022.
T. K. Karikari, “Blood Tests for Alzheimer's Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance.”, J Alzheimers Dis, vol. 90, no. 3, pp. 967-974, 2022.
I. Koychev, Jansen, K., Dette, A., Shi, L., and Holling, H., “Blood-Based ATN Biomarkers of Alzheimer's Disease: A Meta-Analysis.”, J Alzheimers Dis, vol. 79, no. 1, pp. 177-195, 2021.
A. Malishkevich, Marshall, G. A., Schultz, A. P., Sperling, R. A., Aharon-Peretz, J., and Gozes, I., “Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers.”, J Alzheimers Dis, vol. 50, no. 1, pp. 249-60, 2016.
H. - F. Wang, Wan, Y., Hao, X. - K., Cao, L., Zhu, X. - C., Jiang, T., Tan, M. - S., Tan, L., Zhang, D. - Q., Tan, L., and Yu, J. - T., “Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration.”, J Alzheimers Dis, vol. 52, no. 1, pp. 179-90, 2016.
H. - F. Wang, Wan, Y., Hao, X. - K., Cao, L., Zhu, X. - C., Jiang, T., Tan, M. - S., Tan, L., Zhang, D. - Q., Tan, L., and Yu, J. - T., “Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration.”, J Alzheimers Dis, vol. 52, no. 1, pp. 179-90, 2016.
I. A. Clark and Vissel, B., “Broader Insights into Understanding Tumor Necrosis Factor and Neurodegenerative Disease Pathogenesis Infer New Therapeutic Approaches.”, J Alzheimers Dis, vol. 79, no. 3, pp. 931-948, 2021.
A. R. Haeusler, Donnelly, C. J., Periz, G., Simko, E. A. J., Shaw, P. G., Kim, M. - S., Maragakis, N. J., Troncoso, J. C., Pandey, A., Sattler, R., Rothstein, J. D., and Wang, J., “C9orf72 nucleotide repeat structures initiate molecular cascades of disease.”, Nature, vol. 507, no. 7491, pp. 195-200, 2014.
E. Aso, Andrés-Benito, P., Carmona, M., Maldonado, R., and Ferrer, I., “Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.”, J Alzheimers Dis, vol. 51, no. 2, pp. 489-500, 2016.
E. Aso, Andrés-Benito, P., Carmona, M., Maldonado, R., and Ferrer, I., “Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.”, J Alzheimers Dis, vol. 51, no. 2, pp. 489-500, 2016.
K. Ding, Tarumi, T., Zhu, D. C., Tseng, B. Y., Thomas, B. P., Turner, M., Repshas, J., Kerwin, D. R., Womack, K. B., Lu, H., C Cullum, M., and Zhang, R., “Cardiorespiratory Fitness and White Matter Neuronal Fiber Integrity in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 61, no. 2, pp. 729-739, 2018.
E. Rotondo, Galimberti, D., Mercurio, M., Giardinieri, G., Forti, S., Vimercati, R., Borracci, V., Fumagalli, G. G., Pietroboni, A. M., Carandini, T., Nobili, A., Scarpini, E., and Arighi, A., “Caregiver Tele-Assistance for Reduction of Emotional Distress During the COVID-19 Pandemic. Psychological Support to Caregivers of People with Dementia: The Italian Experience.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1045-1052, 2022.
M. A. Burguillos, Deierborg, T., Kavanagh, E., Persson, A., Hajji, N., Garcia-Quintanilla, A., Cano, J., Brundin, P., Englund, E., Venero, J. L., and Joseph, B., “Caspase signalling controls microglia activation and neurotoxicity.”, Nature, vol. 472, no. 7343, pp. 319-24, 2011.
D. Renard, Wacongne, A., Ayrignac, X., Charif, M., Fourcade, G., Azakri, S., Le Floch, A., Bouly, S., Marelli, C., Arquizan, C., Hirtz, C., Gabelle, A., Thouvenot, E., and Lehmann, S., “Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 3, pp. 759-64, 2016.
D. - W. Chen, Wang, J., Zhang, L. - L., Wang, Y. - J., and Gao, C. - Y., “Cerebrospinal Fluid Amyloid-β Levels are Increased in Patients with Insomnia.”, J Alzheimers Dis, vol. 61, no. 2, pp. 645-651, 2018.
M. Carmona-Iragui, Fernández-Arcos, A., Alcolea, D., Piazza, F., Morenas-Rodriguez, E., Antón-Aguirre, S., Sala, I., Clarimón, J., Dols-Icardo, O., Camacho, V., Sampedro, F., Munuera, J., Nuñez-Marin, F., Lleo, A., Fortea, J., Gómez-Ansón, B., and Blesa, R., “Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 1, pp. 1-7, 2016.
A. Kimura, Yoshikura, N., Hayashi, Y., and Inuzuka, T., “Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 581-588, 2018.
A. Kimura, Yoshikura, N., Hayashi, Y., and Inuzuka, T., “Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 581-588, 2018.
M. Bjerke, Kern, S., Blennow, K., Zetterberg, H., Waern, M., Börjesson-Hanson, A., Östling, S., Kern, J., and Skoog, I., “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.

Pages